---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001212"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T15:44:14.226166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q2 2023 revenue $3.88B, GAAP loss $0.77/sh, non-GAAP EPS $0.56; raises revenue guidance

## Summary
- Revenue $3.88B (+2% YoY, +4% local currency); AUSTEDO U.S. rev $308M.
- GAAP net loss $863M ($0.77 loss per share) vs $232M loss in Q2 2022.
- Non-GAAP diluted EPS $0.56, down from $0.68 YoY; non-GAAP operating margin 26.1%.
- Free cash flow $632M; operating cash flow $324M.
- FY 2023 revenue guidance raised to $15.0-$15.4B; all other guidance reaffirmed.

## SEC filing metadata
- accession: 0001157523-23-001212
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/0001157523-23-001212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/a53501990.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001212
- JSON: https://secwatch.observer/filing/0001157523-23-001212.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001212.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended June 30, 2023 results: revenue $3,878 million, EPS GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Revenue: $3,878 million
  - EPS: GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56
  - Guidance: reaffirmed
  - Result: reported results
  source text: structure, while also reorganizing key business units to enhance operational efficiency. Second Quarter 2023 Consolidated Results Revenues in the second quarter of 2023 were $3,878 million, an increase of 2% compared to the second quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from AUSTEDO and Anda in our North
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/0001157523-23-001212-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.